A phase II multicenter trial of mFOLFOX6 as adjuvant treatment after resection of liver metastases from colorectal cancer (Miyagi-HBPCOG Trial-001): The final data of progression-free survival.

Yu Katayose,Kuniharu Yamamoto,Shinichi Takemura,Michinaga Takahashi,Ryuji Nakamura,Hiromune Shimamura,Taku Asanuma,Tetsuyuki Uchiyama,Kojin Endo,Masaya Oikawa,Kenichi Shiiba,Kei Nakagawa,Shinichi Egawa,Michiaki Unno,Miyagi Hbpcog

A phase II multicenter trial of mFOLFOX6 as adjuvant treatment after resection of liver metastases from colorectal cancer (Miyagi-HBPCOG Trial-001): The final data of progression-free survival.

2017

Yu Katayose
Kuniharu Yamamoto
Shinichi Takemura
Michinaga Takahashi
Ryuji Nakamura
Hiromune Shimamura
Taku Asanuma
Tetsuyuki Uchiyama
Kojin Endo
Masaya Oikawa
Kenichi Shiiba
Kei Nakagawa
Shinichi Egawa
Michiaki Unno
Miyagi Hbpcog

e14011 Background: Perioperative chemotherapy with FOLFOX4 reduces the progression-free survival of patients with liver metastases from colorectal cancer. However, the benefit of adjuvant treatment...

Keywords:

Resection
Perioperative
Multicenter trial
Internal medicine
Pathology
Colorectal cancer
Oncology
Adjuvant
Progression-free survival
Medicine
Chemotherapy
perioperative chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations